GHK Peptide Research: Carbonless Analogue Study Findings

A computational study published in Physical Chemistry Chemical Physics (April 2026) by Skurski and Anusiewicz is raising intriguing questions about the future of peptide design. The research introduces the concept of "carbonless" biomolecules — structures in which carbon atoms are systematically replaced by boron and nitrogen — and applies this framework to familiar amino acids and, notably, to the tripeptide Gly-His-Lys, more commonly known as GHK. While this research is theoretical and computational in nature, its implications for understanding peptide structure, conformational flexibility, and metal-binding behavior are worth examining carefully.

What This Study Found

The central premise of this study is an approach called carbonless biomolecular design. Under a principle known as isoelectronicity — the idea that atoms or molecules sharing the same number of electrons can behave in structurally analogous ways — the researchers proposed replacing carbon atoms in biological molecules with boron-nitrogen (BN) pairs. Because a boron atom and a nitrogen atom together contribute the same number of electrons as two carbon atoms, this substitution preserves much of the underlying electronic architecture of the original molecule while eliminating carbon entirely.

Using advanced quantum chemical calculations (specifically DFT at the ωB97XD/aug-cc-pVDZ level) combined with aqueous solvation modeling and conformer sampling techniques, the researchers identified carbonless analogues of three amino acids central to the GHK tripeptide: glycine (Gly), histidine (His), and lysine (Lys). These were designated cGly, cHis, and cLys, respectively. From these building blocks, a carbonless version of the full GHK tripeptide — termed cGHK — was constructed and analyzed.

One of the study's notable findings relates to conformational plasticity. The researchers found that cGHK appears to adopt a broader range of three-dimensional shapes under simulated physiological aqueous conditions compared to native GHK. In molecular science, greater conformational flexibility can influence how a molecule interacts with biological targets, though the researchers make no claims about biological activity at this stage.

The study also modeled how cGHK interacts with copper(II) ions — a well-documented feature of native GHK, which is known to bind copper through a specific coordination motif involving three nitrogen atoms and one oxygen atom (3N1O). Using a thermodynamic analysis called an isodesmic ligand exchange cycle, the researchers calculated that cGHK demonstrates stronger stabilization of copper(II) ions than native GHK, with a calculated free energy difference (ΔGexch) of -6.24 kcal/mol at 298 K. The study suggests that BN substitution may therefore be a viable strategy for tuning metal-binding thermodynamics in peptide-inspired molecules.

It is essential to note that this is a purely computational study. No laboratory synthesis, in vitro cell experiments, or animal or human studies were conducted. The molecules described exist, at this stage, only as mathematical and structural models.

Clinical Significance

To appreciate why this research may matter in a broader biomedical context, it helps to understand the significance of the native GHK tripeptide. GHK (Gly-His-Lys) is a naturally occurring human peptide first identified in human plasma, and it has been studied extensively in peer-reviewed literature for its roles in wound healing, tissue remodeling, and copper transport. Its copper-binding capacity is considered central to many of its studied biological functions.

The finding that a carbonless analogue of GHK might bind copper more strongly than native GHK is scientifically interesting because it raises a theoretical possibility: BN-substituted peptide analogues could potentially be engineered to have enhanced or altered functional properties compared to their carbon-based counterparts. Researchers in medicinal chemistry and drug design are perpetually searching for new molecular scaffolds — structural frameworks on which therapeutically relevant molecules can be built — and carbonless frameworks represent an entirely novel class of such scaffolds.

Additionally, the broader conformational landscape of cGHK suggested by the study could theoretically influence how such a molecule interacts with proteins, receptors, or enzymes. In drug design, conformational flexibility is a double-edged sword: it can increase the range of molecular targets a compound engages, but it can also reduce selectivity. The study suggests that BN substitution offers a new lever for tuning this property.

However, the path from a computational model to a clinically relevant molecule is long and uncertain. The researchers themselves frame their work as a feasibility demonstration. Human data does not yet exist, and significant research — including synthesis, stability testing, toxicological evaluation, and biological activity studies — would be required before any clinical relevance could be established.

Current Access and Compliance Context

It is important to clearly state that cGHK and carbonless amino acids do not exist as commercially available compounds at this time. They are theoretical constructs described in a peer-reviewed computational chemistry study. There are no supplements, injections, or clinical preparations of carbonless peptides available to patients or consumers.

Native GHK and GHK-Cu (the copper-bound form) are used in some cosmetic and research contexts and are studied by peptide researchers globally. Any products currently on the market referencing GHK or GHK-Cu are based on the native, carbon-containing peptide — not the carbonless analogues described in this study.

For individuals interested in peptide therapies broadly, it is critical to work with a qualified, licensed medical professional. Peptide therapies must be obtained through legal, regulated channels, and their use should always be supervised by a physician who can evaluate appropriateness, dosing, and safety on an individual basis. The Peptide Association maintains a directory of knowledgeable practitioners at peptideassociation.org/find-a-doctor.

What Patients Should Know

For patients and interested readers, here are the key takeaways from this research, framed carefully in proportion to what the evidence currently supports:

• This is early-stage computational research. The study uses sophisticated mathematical modeling to predict the properties of molecules that have not yet been physically created. Real-world behavior may differ from computational predictions.
• No human or animal studies have been conducted. The results are theoretical. Significant additional research, including laboratory synthesis and biological testing, would be necessary before any health-related claims could be made.
• The native GHK peptide has an established research history, which is part of why it was chosen as a model system in this study. However, the carbonless cGHK described here is a distinct, novel molecule.
• Boron-nitrogen substitution as a drug design strategy is an active area of scientific investigation. This study contributes a new application of that strategy at the peptide level, suggesting it is a direction worth further exploration by the research community.
• Do not attempt to source or use experimental or uncharacterized peptide compounds outside of supervised clinical or research settings. Patient safety depends on properly evaluated, regulated substances administered under medical supervision.

Conclusion

The study by Skurski and Anusiewicz represents a genuinely novel contribution to the field of peptide science. By demonstrating — at least computationally — that carbonless analogues of amino acids and the GHK tripeptide are theoretically feasible, and that BN substitution may enhance copper-binding affinity and broaden conformational flexibility, the research opens a new conceptual door in biomolecular design. Whether these theoretical advantages will translate into molecules with meaningful biological or therapeutic applications remains an open question that future experimental research will need to address.

Science advances through exactly this kind of foundational, exploratory work. The peptide science community will be watching this area with interest. If you are curious about the current state of peptide research and evidence-based peptide therapies, we encourage you to consult with a qualified medical professional.

Find a knowledgeable peptide-informed physician near you at peptideassociation.org/find-a-doctor.

Medical Disclaimer: This article is intended for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research described is computational in nature; no clinical data exists for the molecules discussed. Always consult a qualified, licensed healthcare provider before beginning, modifying, or discontinuing any medical treatment or therapy. The Peptide Association does not endorse any specific product, treatment, or therapy mentioned in this article.

Citation (AMA Format):
Skurski P, Anusiewicz I. Carbonless amino acids and a carbonless GHK peptide. Phys Chem Chem Phys. 2026. doi:10.1039/d6cp00567e. PMID: 41859865.